News

Media Release

Nabota® successfully registered in Malaysia

Download as PDF

    Singapore, 30 August 2023–Hyphens Pharma International Limited (“Hyphens Pharma”, “凯帆药剂国际有限公司”, or the “Company”, and together with its subsidiaries, the “Group”), Singapore’s leading specialty pharmaceutical and consumer healthcare group, would like to announce that the botulinum toxin formulation Nabota® from Daewoong Pharmaceutical Co., Ltd. (“Daewoong Pharmaceutical”) has been successfully registered in Malaysia on 7 August 2023.

    Botulinum toxin, commonly referred to as botox, is a neuromodulator for cosmetic use, such as facial wrinkle improvement. Nabota® is a premium high-purity botulinum toxin based on Daewoong Pharmaceutical’s patented Hi-PureTM technology that minimises impurities, and is characterised by its high safety, rapid effect, and uniform spreading power. Nabota® is approved by the U.S. Food and Drug Administration and the Company’s subsidiary Hyphens Pharma Sdn. Bhd. will be handling the distribution and sales in Malaysia.

    Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, said: “Following the successful registration in Singapore, we are pleased to be able to bring Nabota® to the Malaysia market with our partner Daewoong Pharmaceutical. Our steady progress with introducing Nabota® to Singapore and Malaysia will allow us to capture a growing market for medical aesthetic products, while further cementing our position as a leading specialty pharmaceutical company in ASEAN.”

    End.

     

    About Hyphens Pharma International Limited

    Hyphens Pharma International Limited and its subsidiaries (the “Group“) is Singapore’s leading specialty pharmaceutical and consumer healthcare group, leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering 10 other markets – Bangladesh, Brunei, Cambodia, China, Hong Kong S.A.R., Macau S.A.R., Myanmar, Oman, South Korea and Sri Lanka.

    Singapore is the Group’s regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group’s core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart & Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies and an online pharmacy for doctors to prescribe and have medications delivered to their patients’ homes.

    For more information, please visit www.hyphensgroup.com

     

    Issued on behalf of Hyphens Pharma International Limited

    For media enquiries, please contact:
    Mr Derek Chng, Tel: (65) 6704 9285, Mob: (65) 9638 8635, Email: [email protected]
    Mr Gerald Woon, Tel: (65) 6704 9268, Mob: (65) 9694 8364, Email: [email protected]

    This media release has been reviewed by the Company’s sponsor, SAC Capital Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this media release, including the correctness of any of the statements or opinions made or reports contained in this media release.

    The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: (65) 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.